Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.
A study looking at samples to predict how people with advanced kidney cancer will respond to drugs that block cancer blood vessel growth (EuroTARGET)
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This study will look at blood and tissue samples and treatment outcome, to see if these will one day help doctors predict how people with kidney cancer will respond to a type of biological therapy called an anti angiogenic.
Cancer cells need a blood supply to bring food and oxygen and remove waste products. To get bigger, a cancer needs to grow its own blood vessels. Angiogenesis means the growth of new blood vessels. So anti angiogenic drugs are biological therapies that stop tumours from growing their own blood vessels.
Doctors can treat people with kidney cancer that has spread to another part of the body with these drugs. But although they help some people, others can have side effects that are so severe that they need to take a lower dose, or stop treatment altogether. Doctors are not yet able to predict who these treatments will work well for, or who will have side effects. So, researchers want to gather information from people having these treatments, which may help in the future.
They will collect samples, and look for differences in people’s DNA that may predict treatment outcome. They will look at how each person responds to their treatment, and see if there are any links between this and what they find in the samples. And, look for proteins and other substances in the cancer that may give information about how sensitive the cancer is to the drug.
The aim of this study is to find ways to better predict the response to anti angiogenic drugs in people with kidney cancer that has spread. You will not have any direct benefit from taking part in this study, and it is unlikely to change your treatment plan in any way. But the results of the study will be used to help people with kidney cancer in the future.
Who can enter
You may be able to enter this study if
- You have the most common type of kidney cancer (renal cell carcinoma)
- Your kidney cancer has spread to another part of your body
- You are at least 18 years old
You cannot enter this study if you would not be able to read and understand the information about it.
This study will recruit 1,100 people across Europe, including 100 people in Cambridge. Everyone will give a sample of blood (about 4 teaspoons), and complete a short questionnaire. The questionnaire will ask
- Whether you smoke
- About any medication you take
- If there is any history of cancer in your family
The study team will also look at your medical notes each year for up to 5 years, to collect information about your treatment and how you responded to it.
If you had surgery to treat your kidney cancer, the team will ask permission to study a small sample of the tissue removed, which is routinely stored by your hospital.
You will give your study blood samples when you are already at the hospital for a routine appointment. So there are no extra hospital visits as part of this study.
You may have a small bruise where you gave your blood sample.
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Tim Eisen
Cambridge University Hospitals NHS Foundation Trust
European Commission (Seventh Framework Programme)
NIHR Clinical Research Network: Cancer
University of Cambridge